---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095526"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:03:14.718554+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atara CEO Pascal Touchon to step down, succeeded by Cokey Nguyen; Q2 net loss narrows to $19M

## Summary
- Pascal Touchon steps down as CEO effective Sep 9, 2024, becomes Chairman; Cokey Nguyen promoted to President and CEO.
- Q2 2024 net loss of $19.0M ($3.10 per share) vs $71.1M loss in Q2 2023; revenue of $28.6M (up from $1.0M).
- Tab-cel BLA accepted with Priority Review, PDUFA target Jan 15, 2025; $20M milestone received from Pierre Fabre.
- Cash, equivalents, short-term investments $35.3M; with milestones and inventory purchase total liquidity $73.2M; cash runway into 2027.
- ATA3219 NHL study enrolling with initial data expected Q1 2025; LN study initiation Q4 2024, data mid-2025.

## SEC filing metadata
- accession: 0000950170-24-095526
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017024095526/0000950170-24-095526-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017024095526/atra-20240810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095526
- JSON: https://secwatch.observer/filing/0000950170-24-095526.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095526.txt

## Key facts
- Executive change
  Pascal Touchon departed as President and Chief Executive Officer at Atara Biotherapeutics, Inc..
  - Action: stepped down
  - Role: President and Chief Executive Officer
  source text: On August 10, 2024, Pascal Touchon notified the Board of Directors (the “Board”) of the Company of his decision to step down as the Company’s President and Chief Executive Officer, effective as of September 9, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017024095526/0000950170-24-095526-index.htm
- Executive change
  Pascal Touchon was appointed as Chairman of the Board at Atara Biotherapeutics, Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: Effective as of the Separation Date, Dr. Touchon will be appointed as Chairman of the Board and will remain a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017024095526/0000950170-24-095526-index.htm
- Executive change
  AnhCo Nguyen was appointed as President and Chief Executive Officer at Atara Biotherapeutics, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On August 10, 2024, the Board appointed AnhCo Nguyen, Ph.D. as the Company’s President and Chief Executive Officer and a member of the Board, effective September 9, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017024095526/0000950170-24-095526-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.